NCT04844359 (PREDICT-HP) is a clinical trial in Hypersensitivity Pneumonitis, sponsored by National Jewish Health.

Who is sponsoring NCT04844359?

NCT04844359 is sponsored by National Jewish Health.

What condition does NCT04844359 study?

NCT04844359 studies Hypersensitivity Pneumonitis.

Is NCT04844359 still recruiting?

NCT04844359 is currently active, enrolled. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT04844359: PREDICT-HP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Active, enrolled Last updated 9 April 2026

What this trial tests

trial in Hypersensitivity Pneumonitis in 137 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 January 2021

Primary endpoint
30 July 2026

31 July 2026

Quick facts

Lead sponsor	National Jewish Health
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	137
Start date	6 January 2021
Primary completion	30 July 2026
Estimated completion	31 July 2026
Sites	7 locations across United States

Conditions studied

Hypersensitivity Pneumonitis — all drugs for Hypersensitivity Pneumonitis →

Sponsor

National Jewish Health — full company profile →

Who can join

Adults 18 to 85, any sex, with Hypersensitivity Pneumonitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rationale and design of the prognostic transcriptomic signature in fibrotic hypersensitivity pneumonitis (PREDICT) study.
Fernández Pérez ER, Leach SM, Vestal B, PREDICT Study Investigators and Collaborators: . · · 2024 · cited 3× · PMID 38264150 · DOI 10.1183/23120541.00625-2023

Verify or expand the search:

Other recruiting trials for Hypersensitivity Pneumonitis

Currently open trials in the same condition.

NCT03800017 — Skeletal Muscle Function in Interstitial Lung Disease · NA · recruiting
NCT05549635 — Database and Biobank of Patients With Hypersensitivity Pneumonitis · recruiting
NCT05392881 — Interstitial Lung Disease Research Unit Biobank · recruiting

Other National Jewish Health trials

Trials by the same sponsor.

NCT06435520 — Enhancing Hypnotic Medication Discontinuation in Primary Care · Phase 4 · recruiting
NCT06262282 — Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria · enrolling by invitation
NCT06155747 — Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt) · recruiting
NCT04724278 — Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study · unknown
NCT05313087 — COVID-19 Vaccine Response in Chronic Respiratory Conditions · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04844359 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Jewish Health
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04844359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing